A cementless, anatomic ceramic hip resurfacing device may be safe and effective, with a low all-cause revision rate at 8-year ...

The FDA has approved once-daily oral Lynkuet for the treatment of moderate to severe hot flashes caused by menopause, ...

Preliminary results presented here showed use of a custom-tailored AI platform may be a feasible option to address ...

Patients staying in hospital rooms with multiple beds are at an increased risk — up to ninefold higher — for Staphylococcus aureus transmission compared with patients in single-bed rooms, according to ...

The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia with a ...

Academic medicine can be a rewarding path filled with opportunities for personal and professional growth, from teaching ...

The FDA declined to approve SYD-101, a low-dose atropine formulation that would have been the first pharmaceutical treatment ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

Topcon Healthcare launched IDHea Inc., a company focused on driving clinical research and oculomics to advance eye care, ...

Among individuals with MS, the risk of serious infection was higher and the time to the first serious infection was shorter ...

In this video, Leo I. Gordon, MD, FACP, discusses how a deeper understanding of minimal residual disease may lead to better care for patients with diffuse large B-cell lymphoma.